MA31519B1 - Compositions d'immunoglobulines lyophilisées et procédés de préparation - Google Patents
Compositions d'immunoglobulines lyophilisées et procédés de préparationInfo
- Publication number
- MA31519B1 MA31519B1 MA32510A MA32510A MA31519B1 MA 31519 B1 MA31519 B1 MA 31519B1 MA 32510 A MA32510 A MA 32510A MA 32510 A MA32510 A MA 32510A MA 31519 B1 MA31519 B1 MA 31519B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- methods
- present
- lyophilized
- immunoglobulin compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne d'une manière générale le domaine des formulations pharmaceutiques d'immunoglobulines. Plus spécifiquement, la présente invention concerne des formulations d'immunoglobuline à haute concentration, stables et lyophilisées. Cette invention concerne par exemple une formulation lyophilisée stabilisée du natalizumab, un anticorps de l'intégrine anti-alpha-4 humanisé recombinant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92913307P | 2007-06-14 | 2007-06-14 | |
US12/138,075 US20090208492A1 (en) | 2007-06-14 | 2008-06-12 | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
PCT/US2008/066990 WO2008157409A1 (fr) | 2007-06-14 | 2008-06-13 | Formulations d'immunoglobuline lyophilisées et procédés de préparation |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31519B1 true MA31519B1 (fr) | 2010-07-01 |
Family
ID=40156638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32510A MA31519B1 (fr) | 2007-06-14 | 2010-01-12 | Compositions d'immunoglobulines lyophilisées et procédés de préparation |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090208492A1 (fr) |
EP (1) | EP2167126A4 (fr) |
JP (1) | JP2010530003A (fr) |
KR (1) | KR20100038100A (fr) |
CN (1) | CN101827608A (fr) |
AU (1) | AU2008265930A1 (fr) |
BR (1) | BRPI0812561A2 (fr) |
CA (1) | CA2691855A1 (fr) |
CO (1) | CO6251275A2 (fr) |
EA (1) | EA201000018A1 (fr) |
EC (1) | ECSP099837A (fr) |
IL (1) | IL202660A0 (fr) |
MA (1) | MA31519B1 (fr) |
MX (1) | MX2009013558A (fr) |
WO (1) | WO2008157409A1 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106075449A (zh) | 2005-07-14 | 2016-11-09 | 尼奥塞蒂克斯公司 | 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂 |
CN101970493A (zh) | 2008-03-14 | 2011-02-09 | 百康有限公司 | 单克隆抗体及其方法 |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
AU2010263058A1 (en) * | 2009-06-18 | 2012-01-12 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
AU2010320515B2 (en) * | 2009-11-20 | 2013-05-02 | Biocon Limited | Formulations of antibody |
KR101638301B1 (ko) * | 2010-01-15 | 2016-07-08 | 네오쎄틱스 인코포레이티드 | 동결건조 케이크 제제 |
MX2012009755A (es) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
WO2011147921A1 (fr) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Compositions stables multi-doses comprenant un anticorps et un agent conservateur |
MY188828A (en) * | 2010-09-17 | 2022-01-06 | Takeda Pharmaceuticals Co | Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
CN105832681A (zh) | 2010-11-24 | 2016-08-10 | 纽赛蒂克斯公司 | 选择性、亲脂性及长效型β激动剂单一治疗调配物和用于肥胖及外形凸起的美容治疗的方法 |
HUE039209T2 (hu) * | 2011-03-31 | 2018-12-28 | Merck Sharp & Dohme | Antitestek stabil formulációi emberi programozott halálreceptor PD-1 ellen és ezzel kapcsolatos kezelések |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
RU2644214C2 (ru) * | 2012-03-26 | 2018-02-08 | Санофи | СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 |
UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
CN105189559B (zh) | 2013-03-15 | 2021-07-13 | 塔科达有限责任公司 | 抗体制剂及其用途 |
KR102034757B1 (ko) | 2013-07-23 | 2019-10-21 | 바이오콘 리미티드 | Cd6 결합 파트너의 용도 및 이에 기초한 방법 |
US20210322549A1 (en) * | 2015-07-17 | 2021-10-21 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Natalizumab |
US10966929B2 (en) | 2015-09-07 | 2021-04-06 | Mochida Pharmaceutical Co., Ltd. | Freeze-dried alginic acid preparation |
MY197672A (en) * | 2016-10-07 | 2023-07-03 | Regeneron Pharma | Room temperature stable lyophilized protein |
KR102514528B1 (ko) | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
BR112020020703A2 (pt) * | 2018-04-10 | 2021-01-12 | Dr. Reddy's Laboratories Limited | Formulações farmacêuticas estáveis de um anticorpo e do anticorpo ¿lfa4¿eta7 . |
US12024561B2 (en) * | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
BR112020020707A2 (pt) * | 2018-04-10 | 2021-01-12 | Dr. Reddy's Laboratories Limited | Formulação farmacêutica estável de um anticorpo alfa4beta7 |
KR20210093976A (ko) | 2018-11-21 | 2021-07-28 | 리제너론 파아마슈티컬스, 인크. | 고농도 단백질 제형 |
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
CN112538111B (zh) * | 2020-12-09 | 2022-04-29 | 深圳市亚辉龙生物科技股份有限公司 | 新冠病毒单链抗体及质控品和制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306404B1 (en) * | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
SI3417875T1 (sl) * | 2003-02-10 | 2021-01-29 | Biogen Ma Inc. | Formulacija imunoglobulina in metode za njegovo pripravo |
US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
-
2008
- 2008-06-12 US US12/138,075 patent/US20090208492A1/en not_active Abandoned
- 2008-06-13 MX MX2009013558A patent/MX2009013558A/es not_active Application Discontinuation
- 2008-06-13 EP EP08771083A patent/EP2167126A4/fr not_active Withdrawn
- 2008-06-13 CN CN200880102173A patent/CN101827608A/zh active Pending
- 2008-06-13 KR KR1020107000761A patent/KR20100038100A/ko not_active Application Discontinuation
- 2008-06-13 WO PCT/US2008/066990 patent/WO2008157409A1/fr active Application Filing
- 2008-06-13 EA EA201000018A patent/EA201000018A1/ru unknown
- 2008-06-13 CA CA002691855A patent/CA2691855A1/fr not_active Abandoned
- 2008-06-13 AU AU2008265930A patent/AU2008265930A1/en not_active Abandoned
- 2008-06-13 BR BRPI0812561-9A2A patent/BRPI0812561A2/pt not_active IP Right Cessation
- 2008-06-13 JP JP2010512402A patent/JP2010530003A/ja active Pending
-
2009
- 2009-12-10 IL IL202660A patent/IL202660A0/en unknown
- 2009-12-28 CO CO09147977A patent/CO6251275A2/es not_active Application Discontinuation
- 2009-12-30 EC EC2009009837A patent/ECSP099837A/es unknown
-
2010
- 2010-01-12 MA MA32510A patent/MA31519B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20090208492A1 (en) | 2009-08-20 |
CA2691855A1 (fr) | 2008-12-24 |
ECSP099837A (es) | 2010-01-29 |
CO6251275A2 (es) | 2011-02-21 |
WO2008157409A8 (fr) | 2010-03-11 |
MX2009013558A (es) | 2010-03-08 |
EA201000018A1 (ru) | 2010-06-30 |
AU2008265930A1 (en) | 2008-12-24 |
IL202660A0 (en) | 2011-08-01 |
CN101827608A (zh) | 2010-09-08 |
JP2010530003A (ja) | 2010-09-02 |
EP2167126A1 (fr) | 2010-03-31 |
EP2167126A4 (fr) | 2012-03-07 |
BRPI0812561A2 (pt) | 2014-10-29 |
WO2008157409A1 (fr) | 2008-12-24 |
KR20100038100A (ko) | 2010-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31519B1 (fr) | Compositions d'immunoglobulines lyophilisées et procédés de préparation | |
MA35153B1 (fr) | Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants | |
TNSN07398A1 (fr) | Anticorps contre la p-cadherine | |
MA33402B1 (fr) | Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps | |
CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
MA30337B1 (fr) | Anticorps | |
MA33387B1 (fr) | Polypeptides et procede de traitement | |
MA30470B1 (fr) | Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste. | |
MA30345B1 (fr) | Formulation d'anticorps monoclonal humain anti-igf-1r | |
MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
UA107211C2 (uk) | Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r) | |
JO3000B1 (ar) | مركبات أجسام مضادة . | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
MA30653B1 (fr) | Anticorps monoclonaux anti-il-6 et leurs utilisations | |
GEP20104922B (en) | Antibodies to m-csf | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
JP2021113217A (ja) | Ksp阻害剤および抗cd123抗体を含む特異的抗体−薬物−コンジュゲート(adc) | |
MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
MY169272A (en) | Her2 antibody composition | |
MA30975B1 (fr) | Formulation parenterale d'anticorps anti-peptide abeta | |
MX2020009275A (es) | Composiciones de anticuerpo anti-pd-1. | |
Li et al. | Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin | |
MA33561B1 (fr) | Dérivés d'isoxazolidine |